SCHEMBL7604446

SCHEMBL7604446

CCCN(C(=O)Cc1cccc(CC)c1)C1CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR5 P51681 2/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
OPRM1 P35372 2/20 0.41
UBE2M P61081 2/20 0.40
DCUN1D1 Q96GG9 2/20 0.40
SLC6A4 P31645 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
KCNH2 Q12809 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MC4R P32245 1/20 0.39
MC5R P33032 1/20 0.39
MC3R P41968 1/20 0.39
SLC6A2 P23975 1/20 0.39
SLC6A3 Q01959 1/20 0.39
PKM P14618 1/20 0.38
SMYD3 Q9H7B4 1/20 0.38
LMNA P02545 1/20 0.38
GRIN2D O15399 1/20 0.38
GRIN3B O60391 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5986720 0.86 EPHX2 (0.47) CCR5UBE2MDCUN1D1SLC6A4KCNH2
SCHEMBL13434093 0.85 CCR5 (0.53) CCR5MEN1KMT2AOPRM1SLC6A4
SCHEMBL13434179 0.85 MRGPRX4 (0.44) CCR5MEN1KMT2AOPRM1SLC6A4
SCHEMBL7601823 0.85 CYP4F2 (0.50) SMN1; SMN2
SCHEMBL13461336 0.84 UBE2M (0.43) CCR5MEN1KMT2AOPRM1UBE2M
SCHEMBL5987120 0.84 CCR5 (0.42) CCR5MEN1KMT2AOPRM1SLC6A4
SCHEMBL5986487 0.83 CCR5 (0.48) CCR5KCNH2
SCHEMBL13434178 0.83 DCUN1D1 (0.45) CCR5DCUN1D1SLC6A4KCNH2SLC6A2
SCHEMBL7601829 0.82 NPC1 (0.39) CCR5MEN1KMT2AUBE2MDCUN1D1
SCHEMBL13434181 0.80 CCR5 (0.42) CCR5OPRM1UBE2MDCUN1D1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8658639-B2 N-substituted-cyclic amino derivative DAINIPPON SUMITOMO PHARMA CO., LTD (JP) 2014-02-25 US disclosed
US-8389511-B2 Bicyclic heterocyclic derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-03-05 US disclosed
US-20120122773-A1 N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-05-17 US disclosed
US-20110190278-A1 BICYCLIC HETEROCYCLIC DERIVATIVE DAINIPPON SUMITOMO PHARMA CO. 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190278-A1 BICYCLIC HETEROCYCLIC DERIVATIVE REN, AGTR1, AGTR2 CCR5 2779/4885MEN1 1068/4885KMT2A 1812/4885
US-20120122773-A1 N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE REN, AGTR1, AGTR2 CCR5 1843/4885MEN1 1004/4885KMT2A 1646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.